When considering reviews that focused on NSCLC, these reviews did not consider appraisals performed by NICE, but analysed cost-effectiveness of targeted mutations, such as EGFR and ALK, [11, 12] or immune checkpoint inhibitors within NSCLC [13, 14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.